What is the Padua Score?
The Padua Prediction Score is a validated risk assessment model (RAM) developed at the University of Padua, Italy, to identify hospitalized medical patients at high risk for venous thromboembolism (VTE). Published by Barbar et al. in 2010 in the Journal of Thrombosis and Haemostasis, it has become one of the most widely used tools for VTE risk stratification in medical inpatients.
The score evaluates 11 risk factors, each assigned a weighted point value based on their relative contribution to VTE risk. The total score determines whether a patient should receive pharmacological thromboprophylaxis during hospitalization.
Scoring System
| Risk Factor | Points |
|---|---|
| Active cancer (local or distant metastases, chemotherapy or radiotherapy within 6 months) | 3 |
| Previous VTE (excluding superficial vein thrombosis) | 3 |
| Reduced mobility (anticipated bed rest with bathroom privileges for ≥3 days) | 3 |
| Already known thrombophilic condition (Factor V Leiden, prothrombin G20210A, protein C/S deficiency, antithrombin deficiency, antiphospholipid syndrome) | 3 |
| Recent (≤1 month) trauma and/or surgery | 2 |
| Elderly age (≥70 years) | 1 |
| Heart and/or respiratory failure | 1 |
| Acute myocardial infarction or ischemic stroke | 1 |
| Acute infection and/or rheumatologic disorder | 1 |
| Obesity (BMI ≥30 kg/m²) | 1 |
| Ongoing hormonal treatment (HRT, oral contraceptives) | 1 |
Score Interpretation
| Score | Risk Category | VTE Incidence | Recommendation |
|---|---|---|---|
| < 4 | Low Risk | 0.3% (11-day cumulative) | No pharmacological prophylaxis needed; consider early ambulation and mechanical prophylaxis |
| ≥ 4 | High Risk | 11.0% (11-day cumulative) | Pharmacological VTE prophylaxis recommended (e.g., LMWH, UFH, fondaparinux) |
In the original validation study, the 11-day VTE incidence was 0.3% in the low-risk group versus 11.0% in the high-risk group, representing a nearly 40-fold difference in risk.
Risk Assessment Diagram
VTE Prevention in Hospitalized Patients
Venous thromboembolism, which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of preventable hospital death. Up to 10% of hospital deaths are attributed to PE. Despite this, studies consistently show that VTE prophylaxis is underutilized in medical patients.
The Padua Score was specifically designed to address this gap by providing a simple, bedside-applicable tool to identify which medical inpatients warrant pharmacological prophylaxis. Unlike surgical patients, who almost universally receive thromboprophylaxis, medical patients have more heterogeneous risk profiles requiring individualized assessment.
- Non-pharmacological measures: Early ambulation, graduated compression stockings, intermittent pneumatic compression devices
- Pharmacological prophylaxis: Low-molecular-weight heparin (LMWH) such as enoxaparin, unfractionated heparin (UFH), or fondaparinux
- Duration: Typically for the duration of hospitalization or until the patient is fully mobile; extended prophylaxis (up to 45 days) may be considered in selected high-risk patients
Anticoagulation Prophylaxis
For patients scoring ≥4 on the Padua Score, pharmacological VTE prophylaxis is recommended unless contraindicated. The following agents and dosages are commonly used:
| Agent | Prophylactic Dose | Notes |
|---|---|---|
| Enoxaparin (LMWH) | 40 mg SC daily | Most studied agent; dose adjustment for renal impairment (CrCl <30: 30mg daily) |
| Unfractionated Heparin | 5,000 units SC q8-12h | Preferred in severe renal impairment; easier to reverse |
| Fondaparinux | 2.5 mg SC daily | Alternative for heparin-induced thrombocytopenia (HIT); contraindicated if CrCl <30 |
| Rivaroxaban | 10 mg PO daily | Studied in MAGELLAN trial; higher bleeding risk limited adoption |
Before initiating prophylaxis, assess for contraindications including active bleeding, severe thrombocytopenia (platelets <50,000), recent intracranial hemorrhage, or planned invasive procedures.
DVT and Pulmonary Embolism
Deep Vein Thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower extremities. Symptoms include unilateral leg swelling, pain, warmth, and erythema. However, many DVTs are asymptomatic, particularly in hospitalized patients.
Pulmonary Embolism (PE) occurs when a clot dislodges and travels to the pulmonary vasculature. PE can present with sudden dyspnea, pleuritic chest pain, tachycardia, and hemoptysis. Massive PE can cause cardiovascular collapse and sudden death. PE is the most feared complication of untreated DVT, occurring in approximately 50% of untreated proximal DVTs.
Risk factors for VTE include immobility, surgery, cancer, inherited thrombophilias, obesity, pregnancy, hormonal therapy, and advanced age. The Padua Score captures the most clinically significant of these factors in the medical inpatient setting.
Worked Example
A 72-year-old patient is admitted with community-acquired pneumonia. The patient has a history of breast cancer treated with chemotherapy 4 months ago and a BMI of 32.
- Active cancer: +3 points
- Age ≥ 70: +1 point
- Acute infection: +1 point
- Obesity (BMI ≥ 30): +1 point
With a score of 6, this patient is at high risk for VTE. Pharmacological prophylaxis with enoxaparin 40 mg subcutaneously daily should be initiated unless contraindicated by active bleeding or severe thrombocytopenia.
Frequently Asked Questions
Who should be assessed with the Padua Score?
The Padua Score is designed for acutely ill medical patients admitted to the hospital. It is not intended for surgical patients (who have separate risk assessment models such as the Caprini score) or for outpatients.
How often should the score be reassessed?
The Padua Score should be calculated at admission and reassessed when there is a significant change in the patient's clinical status, such as new immobility, development of infection, or diagnosis of cancer. Many institutions incorporate it into daily nursing or physician assessments.
Can the Padua Score be used in surgical patients?
No. The Padua Score was validated specifically for medical inpatients. For surgical patients, the Caprini Risk Assessment Model is more appropriate. Surgical patients generally require routine thromboprophylaxis due to the inherent VTE risk of surgery and anesthesia.
What if pharmacological prophylaxis is contraindicated?
For high-risk patients who cannot receive anticoagulant prophylaxis (due to active bleeding, severe thrombocytopenia, etc.), mechanical prophylaxis with intermittent pneumatic compression (IPC) devices should be applied. Graduated compression stockings may be used as an adjunct but are less effective alone. Reassess daily for the ability to initiate pharmacological prophylaxis.
Is the Padua Score endorsed by guidelines?
Yes. The Padua Score is recommended by the American College of Chest Physicians (ACCP), the International Society on Thrombosis and Haemostasis (ISTH), and the National Institute for Health and Care Excellence (NICE) as a validated tool for VTE risk assessment in medical inpatients.